CNTA Quote, Financials, Valuation and Earnings

Autolus Therapeutics Plc has a net margin of -174.23% compared to Centessa Pharmaceuticals Plc's net margin of -373.3%. Centessa Pharmaceuticals Plc's return on equity of -62.59% beat Autolus Therapeutics Plc's return on equity of -59.51%.

Centessa Pharmaceuticals Plc has a consensus price target of $37.67, signalling upside risk potential of 53.06%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 470.19%. Given that Autolus Therapeutics Plc has higher upside potential than Centessa Pharmaceuticals Plc, analysts believe Autolus Therapeutics Plc is more attractive than Centessa Pharmaceuticals Plc.

Centessa Pharmaceuticals Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.

Centessa Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centessa Pharmaceuticals Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.

Centessa Pharmaceuticals Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Centessa Pharmaceuticals Plc's net income of -$54.6M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Centessa Pharmaceuticals Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centessa Pharmaceuticals Plc is 224.12x versus 8.67x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals Plc has a net margin of -174.23% compared to Centessa Pharmaceuticals Plc's net margin of --. Centessa Pharmaceuticals Plc's return on equity of -62.59% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

Centessa Pharmaceuticals Plc has a consensus price target of $37.67, signalling upside risk potential of 53.06%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 6662.41%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Centessa Pharmaceuticals Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Centessa Pharmaceuticals Plc.

Centessa Pharmaceuticals Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.

Centessa Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centessa Pharmaceuticals Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Centessa Pharmaceuticals Plc quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Centessa Pharmaceuticals Plc's net income of -$54.6M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Centessa Pharmaceuticals Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centessa Pharmaceuticals Plc is 224.12x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

NuCana Plc has a net margin of -174.23% compared to Centessa Pharmaceuticals Plc's net margin of --. Centessa Pharmaceuticals Plc's return on equity of -62.59% beat NuCana Plc's return on equity of -286.82%.

Centessa Pharmaceuticals Plc has a consensus price target of $37.67, signalling upside risk potential of 53.06%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 628298.79%. Given that NuCana Plc has higher upside potential than Centessa Pharmaceuticals Plc, analysts believe NuCana Plc is more attractive than Centessa Pharmaceuticals Plc.

Centessa Pharmaceuticals Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.

Centessa Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centessa Pharmaceuticals Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.

Centessa Pharmaceuticals Plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Centessa Pharmaceuticals Plc's net income of -$54.6M is lower than NuCana Plc's net income of -$378.9K. Notably, Centessa Pharmaceuticals Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centessa Pharmaceuticals Plc is 224.12x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.

Tiziana Life Sciences Ltd. has a net margin of -174.23% compared to Centessa Pharmaceuticals Plc's net margin of --. Centessa Pharmaceuticals Plc's return on equity of -62.59% beat Tiziana Life Sciences Ltd.'s return on equity of --.

Centessa Pharmaceuticals Plc has a consensus price target of $37.67, signalling upside risk potential of 53.06%. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $7.99 which suggests that it could grow by 439.75%. Given that Tiziana Life Sciences Ltd. has higher upside potential than Centessa Pharmaceuticals Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Centessa Pharmaceuticals Plc.

Centessa Pharmaceuticals Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of -0.047, suggesting its less volatile than the S&P 500 by 104.653%.

Centessa Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centessa Pharmaceuticals Plc pays -- of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend.

Centessa Pharmaceuticals Plc quarterly revenues are --, which are larger than Tiziana Life Sciences Ltd. quarterly revenues of --. Centessa Pharmaceuticals Plc's net income of -$54.6M is higher than Tiziana Life Sciences Ltd.'s net income of --. Notably, Centessa Pharmaceuticals Plc's price-to-earnings ratio is -- while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centessa Pharmaceuticals Plc is 224.12x versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.